Currently, there are three main anti-VEGF agents available in clinical practice to manage wet AMD: ranibizumab (RBZ), aflibercept (AFB) and bevacizumab (BVZ), the latter used off-label. The gene discussed is VEGFA; the disease is wet macular degeneration.